Liquidia CORP

Liquidia Corporation has reached a global settlement agreement with United Therapeutics Corporation, resolving all ongoing litigation and ensuring the continued availability of YUTREPIA for PAH patients.

Liquidia Corporation received an unfavorable ruling in its Hatch-Waxman litigation concerning the 327 patent, with two key claims found valid and infringed, potentially impacting YUTREPIA's market access.

Liquidia Corporation announced that the U.S. FDA has granted Fast Track designation to YUTREPIA (treprostinil) inhalation powder for the treatment of Raynaud's phenomenon associated with systemic sclerosis (SSc-RP).

Liquidia Corporation announced robust second quarter 2026 financial results, highlighted by a 31% sequential increase in YUTREPIA net product sales to $170.4 million and a fourth consecutive quarter of increasing profitability.

Liquidia Corporation announced the results of its annual meeting of stockholders held on June 16, 2026, including the election of directors and ratification of its accounting firm.

Liquidia Corporation announced its inclusion in the S&P SmallCap 600 Index, effective June 22, 2026, reflecting its growth and market position.

Liquidia Corporation reported a substantial increase in product sales driven by YUTREPIA, alongside significant investments in research and development and ongoing litigation.

Liquidia Corporation announced a substantial increase in revenue for the first quarter of 2026, driven by strong product sales of YUTREPIA.

Liquidia Corporation reports significant revenue growth driven by the commercial launch of YUTREPIA, alongside a reduced net loss, but faces ongoing patent and trade secret litigation and increased debt.

Liquidia Corporation reports increased losses and expenses in Q2 2025 despite the commercial launch of its key drug YUTREPIA, as it navigates multiple high-stakes patent and trade secret litigations.

Liquidia Corporation reports Q1 2025 results with a net loss of $38.4 million and expresses substantial doubt about its ability to continue as a going concern without additional funding.

Liquidia Corporation received tentative FDA approval for YUTREPIA, while facing patent litigation and securing significant funding through a public offering and a private placement.

Liquidia Corporation achieved its first product sales of YUTREPIA in 2025, generating $148.3 million, but faces significant ongoing litigation and continued net losses.

Liquidia Corporation's 2024 10-K filing highlights the company's focus on cardiopulmonary diseases, the anticipated launch of YUTREPIA pending regulatory exclusivity, and ongoing legal challenges.

Liquidia Corporation's 10-K filing details its financial status, product pipeline, ongoing litigation, and strategic agreements.

Russell Schundler, General Counsel of Liquidia Corp, sold 13,692 shares of common stock on October 9, 2026 for $28.48 per share.

Rajeev Saggar, Chief Medical Officer of Liquidia Corp, sold 9,218 shares of common stock on October 9, 2026 for $28.48 per share.

Scott Moomaw, Chief Commercial Officer of Liquidia Corp, sold 8,863 shares of common stock on October 9, 2026 for $28.48 per share.

Sarah Krepp, Chief Human Resource Officer of Liquidia Corp, sold 5,245 shares of common stock on October 9, 2026 for $28.48 per share.

Sanjeev Khindri, Chief Development Officer of Liquidia Corp, sold 1,101 shares of common stock on October 12, 2026 for $28.48 per share.

Michael Kaseta, CFO and COO of Liquidia Corp, sold 18,938 shares of common stock on October 9, 2026 for $28.48 per share.

Liquidia Corporation reports strong commercial success for YUTREPIA and outlines strategic growth plans in its 2026 proxy statement.

Liquidia Corporation will hold its 2025 Annual Stockholders Meeting virtually on June 17, 2025, to vote on director elections, auditor ratification, and executive compensation.

Liquidia Corporation will hold its 2025 Annual Meeting of Stockholders virtually on June 17, 2025, to vote on director elections, auditor ratification, and executive compensation.

Liquidia Corporation will hold its 2024 Annual Stockholders Meeting virtually on June 20, 2024, to vote on key proposals including the election of directors and an amendment to increase authorized shares.

Liquidia Corporation's upcoming annual meeting on June 20, 2024, will address director elections, an increase in authorized common stock, auditor ratification, and advisory votes on executive compensation.

Paul B. Manning and associated entities report beneficial ownership of 6.5% of Liquidia Corp's common stock as of June 30, 2026, with no changes in reporting status.

Farallon Capital Management, L.L.C. and its affiliates have reported beneficial ownership of 8,365,038 shares, representing 9.4% of the common stock of Liquidia Corporation.

BlackRock, Inc. has filed a Schedule 13G, reporting beneficial ownership of 11.9% of Liquidia Corp's common stock as of June 30, 2026.

Farallon Capital and its affiliates have filed an amended Schedule 13G, reporting a collective beneficial ownership of 9.9% in Liquidia Corporation and detailing recent management changes within Farallon.

Farallon Capital and its affiliated entities have filed an amended Schedule 13G, disclosing a collective beneficial ownership of 9.95% of Liquidia Corporation's common stock.

Farallon Capital and its affiliated entities, including various funds and managing members, have collectively reported beneficial ownership of 8% of Liquidia Corporation's common stock.